{
    "clinical_study": {
        "@rank": "106028", 
        "arm_group": [
            {
                "arm_group_label": "Rivaroxaban", 
                "arm_group_type": "Experimental", 
                "description": "Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing"
            }, 
            {
                "arm_group_label": "Marcumar", 
                "arm_group_type": "Active Comparator", 
                "description": "Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
            }
        ], 
        "brief_summary": {
            "textblock": "The following  trial hypothesis will be proved: In patients with atrial fibrillation and/ or\n      pulmonary embolism standard anticoagulant treatment with coumadin/phenprocoumon is\n      associated with accelerated coronary or valvular calcification as assessed by cardiac\n      computed tomography compared to the new anticoagulant therapy with rivaroxaban."
        }, 
        "brief_title": "Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation or Pulmonary Embolism", 
            "Need of Long Term Oral Anticoagulation Therapy (OAT)", 
            "Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Calcinosis", 
                "Embolism", 
                "Pulmonary Embolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "A single center, prospective, controlled, open, randomized, interventional clinical trial\n      blinded concerning outcome measurements with a two- arm parallel group design will be\n      performed to investigate the association of rivaroxaban compared to coumadin/phenprocoumon\n      treatment for OAT in patients with atrial fibrillation and / or pulmonary embolism regarding\n      the development and progression of coronary artery calcification (CAC) and aortic valve\n      calcification (AVC) as assessed by multi-slice spiral computed tomography scanning (MSCT)\n      within one year follow-up. In total 348 patients (174 patients per treatment arm including\n      calculated drop outs and invalid cases) with atrial fibrillation and/ or pulmonary embolism\n      with the indication for oral anticoagulation therapy will be enrolled. After screening first\n      cardiac CT scan will be performed in order to validate if calcium score is >50 which is an\n      inclusion criteria. If the patient matches all other inclusion/exclusion criteria the\n      remaining imaging procedures (Echocardiography, Intima  Media Thickness of carotid artery\n      (IMT) and Flow Mediated Vasodilatation (FMD), Electrocardiography (ECG) and blood pressure\n      are executed. Pregnancy strip test will  be executed and also serum chemistry, hematology,\n      coagulation and batch analysis will be performed. Patients will then be randomized to one of\n      the two arms (Rivaroxaban or Marcumar) and will undergo the same examinations and\n      measurements as described above at 1 week, 1, 6, 9 and 12 month Follow- Up (FU). In case of\n      a positive result in respect to the primary endpoint  a FU after 2 years will be performed\n      optionally."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female patient aged > 18 years\n\n          2. Need for long-term OAT according to current international guidelines for the\n             treatment of atrial fibrillation (ACC/(American Heart Association [AHA]/ European\n             Society of Cardiology [ESC]guidelines) and / or pulmonary embolism (ACCP/ESC\n             guidelines).\n\n          3. Existent Coronary or Valvular Calcification, or both and an Agatston Score > 50 in at\n             least one location as assessed by MSCT at Screening\n\n          4. PROCAM Score \u2265 29\n\n          5. The anticipated minimum life expectancy is18 months\n\n        Exclusion Criteria:\n\n          1. Patient has any clinical condition which does not allow initiation of long-term OAT\n             including all contraindications such as hypersensitivity to active ingredient or\n             other excipients, clinically relevant acute bleedings and all other risk\n             circumstances according to Summary of Medicinal Product (SmPC) in which all warnings\n             and preventive measures and precautions are described and have to be kept.\n\n          2. Hypersensitivity to active substances investigated or to any of the excipients\n\n          3. Patients had a previous coronary stent implantation and no Valvular Calcification\n             with Agatston Score > 50\n\n          4. Chronic kidney disease (CKD) Stage V (GFR <15 mL)\n\n          5. Liver disease with coagulopathy or other bleeding disorders including cirrhotic\n             patients with Child Pugh B and C\n\n          6. Acute gastrointestinal diseases\n\n          7. Clinically significant active bleeding\n\n          8. Alcohol, opioids or drug abuse\n\n          9. Mental condition rendering the patient unable to understand the nature, scope and\n             possible consequences of the study\n\n         10. Patient is unwilling or unable to give informed consent\n\n         11. Patient is unlikely to comply with protocol, e.g. uncooperative attitude, inability\n             to return for follow-up visits, and unlikelihood of completing the study\n\n         12. Participation in a parallel interventional clinical trial\n\n         13. Patient has been committed to an institution by legal or regulatory order\n\n         14. Pregnant or lactating women\n\n         15. Female patient capable of bearing children without highly effective methods of birth\n             control\n\n         16. Patient receives concomitant treatment with strong concurrent Cytochrome P 450 3A4\n             (CYP3A4)- and P- glycoprotein (P-gp)- inhibitors, i.e. azole-antimycotics\n             (ketoconazole, itraconazole) or human immunodeficiency virus (HIV) protease\n             inhibitors\n\n         17. Neuraxial Anaesthesia or spinal/epidural puncture\n\n         18. Known Endocarditis\n\n         19. Known Lactose intolerance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "348", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066662", 
            "org_study_id": "12-001"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rivaroxaban", 
                "Marcumar"
            ], 
            "description": "Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;\nArm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.", 
            "intervention_name": "Rivaroxaban or Marcumar", 
            "intervention_type": "Drug", 
            "other_name": "Xarelto; Marcumar"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Phenprocoumon", 
                "Vitamin K", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Coronary or Valvular Calcification", 
            "Agatston Score", 
            "Rivaroxaban", 
            "Coumarin", 
            "Oral Anticoagulation Therapy (OAT)", 
            "Atrial Fibrillation", 
            "Pulmonary Embolism"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "contact": {
                "email": "rkoos@ukaachen.de", 
                "last_name": "Ralf Koos, PD Dr. med.", 
                "phone": "0049 241 80", 
                "phone_ext": "89833"
            }, 
            "contact_backup": {
                "email": "sgloeggler@ukaachen.de", 
                "last_name": "Sigrid Gloeggler, M.Sc.", 
                "phone": "0049 241 80", 
                "phone_ext": "80202"
            }, 
            "facility": {
                "address": {
                    "city": "Aachen", 
                    "country": "Germany", 
                    "state": "North Rhine Westphalia", 
                    "zip": "52074"
                }, 
                "name": "University Hospital Aachen, Department of Cardiology"
            }, 
            "investigator": [
                {
                    "last_name": "Ralf Koos, PD Dr. med.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Vincent Brandenburg, PD Dr. med.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism", 
        "other_outcome": [
            {
                "measure": "Occurrence of major cardiovascular complications (MACE)", 
                "safety_issue": "Yes", 
                "time_frame": "1 week, 1, 6, 9, 12 month FU"
            }, 
            {
                "measure": "Non- major bleedings", 
                "safety_issue": "Yes", 
                "time_frame": "1week, 1, 6, 9, 12 month FU"
            }, 
            {
                "measure": "Major bleedings", 
                "safety_issue": "Yes", 
                "time_frame": "1 week, 6, 9, 12 month FU"
            }
        ], 
        "overall_contact": {
            "email": "rkoos@ukaachen.de", 
            "last_name": "Ralf Koos, PD Dr. med.", 
            "phone": "0049 241 80", 
            "phone_ext": "89833"
        }, 
        "overall_contact_backup": {
            "email": "sgloeggler@ukaachen.de", 
            "last_name": "Sigrid Gloeggler, M.Sc.", 
            "phone": "0049 241 80", 
            "phone_ext": "80202"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To investigate the association of rivaroxaban compared to coumadin/phenprocoumon treatment for OAT in patients with atrial fibrillation and / or pulmonary embolism regarding the development and progression of coronary artery calcification (CAC) and aortic valve calcification (AVC) as assessed by multi-slice spiral computed tomography scanning (MSCT) within one year follow-up", 
            "measure": "Progression of coronary and aortic valve calcification (Agatston Score)", 
            "safety_issue": "Yes", 
            "time_frame": "Cardiac Computertomography (CT) will be performed at screening, after 12 months and optional at 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066662"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum chemistry including Matrix Gla Protein (MPG) level changes and Fetuin-A (baseline/ follow up)", 
                "safety_issue": "No", 
                "time_frame": "baseline and 12 month Follow Up"
            }, 
            {
                "measure": "Changes in intima-media thickness of carotid artery (IMT) and flow-mediated vasodilation of brachial artery (FMD)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 6, 9 and 12 month FU"
            }, 
            {
                "measure": "Progression of aortic calcification (aortic Agatston Score)", 
                "safety_issue": "No", 
                "time_frame": "screening and 12 month FU"
            }, 
            {
                "measure": "Changes in ventricular diastolic function parameters as determined by echocardiography (strain/strain-rate imaging)", 
                "safety_issue": "No", 
                "time_frame": "baseline, 6, 9 and 12 month FU"
            }
        ], 
        "source": "RWTH Aachen University", 
        "sponsors": {
            "collaborator": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "RWTH Aachen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}